A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 450 participants.
Also called NCT07931547
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 450 participants
- Sponsor
- Registry
-
NCT07931547
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Brazil, China, Czechia, Germany, India, Japan, Poland, South Korea, Türkiye
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07931547. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-10 (anticipated); primary completion 2028-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
- Acronym
- AMBITION 2
- Condition
- Type 2 Diabetes
- Condition
- Chronic Kidney Disease
- Intervention (Other)
- Placebo
- Intervention (Drug)
- Zenagamtide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07931547- Content hash
a8a1f6afc484315789432cac114d81dec53bcfbc6edda30fa0807d3b545ffff6